טוען...
OR31-1 Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk of Diabetic Ketoacidosis: Clinical and Biochemical Characteristics of 21 Cases
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i’s) are the newest class of anti-hyperglycemic drugs. Their mechanism of action involves increasing urinary glucose excretion by preventing glucose reabsorption in the proximal renal tubules, yet they can also promote ketogenesis under cer...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6554857/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR31-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|